首站-论文投稿智能助手
典型文献
Interleukins in the treatment of melanoma
文献摘要:
Interleukins (ILs) and associated cytokines serve as the means of communication for immune cells and non-immune cells. The use of ILs in harnessing the immune system to cancer treatment has been a promising approach. ILs not only nurture an environment enabling cancer growth but also simultaneously trigger a productive tumor-directed immune response. These properties of ILs are increasingly being explored as a strategy to improve the outcomes of cancer. Here, we describe recently innovative technological approaches that have been developed to improve the pharmacokinetics, safety, and efficacies of IL-2, 15, 10, and 18 in the treatment of melanoma. Furthermore, the combination of ILs and immune checkpoint inhibition may synergize to reshape the tumor environment, thus yielding better clinical benefits in the future.
文献关键词:
IL-2;IL-15;IL-10;IL-18;Melanoma;Immunotherapy
作者姓名:
Xu Xinyuan;Dai Wei;Li Chunying
作者机构:
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, China
引用格式:
[1]Xu Xinyuan;Dai Wei;Li Chunying-.Interleukins in the treatment of melanoma)[J].中华医学杂志(英文版),2022(04):393-399
A类:
Interleukins
B类:
treatment,melanoma,ILs,associated,cytokines,serve,means,communication,immune,cells,use,harnessing,system,cancer,has,been,promising,only,nurture,environment,enabling,growth,but,also,simultaneously,trigger,productive,tumor,directed,response,These,properties,are,increasingly,being,explored,strategy,improve,outcomes,Here,we,describe,recently,innovative,technological,approaches,that,have,developed,pharmacokinetics,safety,efficacies,Furthermore,combination,checkpoint,inhibition,may,synergize,reshape,thus,yielding,better,clinical,benefits,future,Melanoma,Immunotherapy
AB值:
0.617285
相似文献
Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis
Haoran Mu;Dongqing Zuo;Jie Chen;Zhigang Liu;Zhuo Wang;Liu Yang;Qihui Shi;Yingqi Hua-Shanghai Bone Tumor Institute and Department of Orthopedics,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China;Key Laboratory of Systems Biomedicine(Ministry of Education),Shanghai Center for Systems Biomedicine,Shanghai Jiao Tong University,Shanghai 200240,China;Shanghai Key Laboratory of Medical Epigenetics and the International Co-laboratory of Medical Epigenetics and Metabolism(MOST),Institutes of Biomedical Sciences,Fudan University,Shanghai 200032,China;Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer(SMHC)and Institute of Fudan-Minhang Academic Health System,Minhang Hospital,Fudan University,Shanghai 201199,China;Shanghai Engineering Research Center of Biomedical Analysis Reagents,Shanghai 201203,China
Pharmacodynamic,pharmacokinetic,and phase 1a study of bisthianostat,a novel histone deacetylase inhibitor,for the treatment of relapsed or refractory multiple myeloma
Yu-bo Zhou;Yang-ming Zhang;Hong-hui Huang;Li-jing Shen;Xiao-feng Han;Xiao-bei Hu;Song-da Yu;An-hui Gao;Li Sheng;Ming-bo Su;Xiao-li Wei;Yue Zhang;Yi-fan Zhang;Zhi-wei Gao;Xiao-yan Chen;Fa-jun Nan;Jia Li;Jian Hou-National Center for New Drug Screening,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Yantai Key Laboratory of Nanomedicine&Advanced Preparations,Yantai Institute of Materia Medica,Yantai 264000,China;Department of Hematology,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Shanghai Center for Drug Metabolism and Pharmacokinetics Research,Shanghai 201203,China
Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells
Changfa Shu;Xi Zheng;Alafate Wuhafu;Danielle Cicka;Sean Doyle;Qiankun Niu;Dacheng Fan;Kun Qian;Andrey A.Ivanov;Yuhong Du;Xiulei Mo;Haian Fu-Department of Pharmacology and Chemical Biology,Emory University School of Medicine,Atlanta,GA 30322,USA;Department of Gynecology and Obstetrics,The Third Xiangya Hospital of Central South University,Changsha 410013,China;Cancer Institute,the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310052,China;The First Affiliated Hospital,Medical School of Xi'an Jiaotong University,Xi'an 710061,China;Emory Chemical Biology Discovery Center,Emory University School of Medicine,Atlanta,GA 30322,USA;Department of Hematology and Medical Oncology and Winship Cancer Institute,Emory University,Atlanta,GA 30322,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。